Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity

摘要

PurposeThe aim of the study was to assess the outcomes of severe retinopathy of prematurity (ROP) in zone I or posterior zone II treated with intravitreal ranibizumab (IVR) as monotherapy or combined treatment with laser photocoagulation.